Athira Pharma, Inc.
US ˙ NasdaqCM ˙ US04746L1044

Introduction

This page provides a comprehensive analysis of the known insider trading history of Mark James Litton. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Mark James Litton has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ATHA / Athira Pharma, Inc. President and CEO, Director 325,802
US:ALPN / Alpine Immune Sciences, Inc. See Remarks 75,000
US:ALDR / Alder BioPharmaceuticals, Inc. Chief Business Officer 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Mark James Litton. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ATHA / Athira Pharma, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ATHA / Athira Pharma, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ATHA / Athira Pharma, Inc. Insider Trades
Insider Sales ATHA / Athira Pharma, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ATHA / Athira Pharma, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-07-01 ATHA Litton Mark James 25,123 0.2935 25,123 0.2935 7,374 0 0.3000 164 2.22
2025-01-02 ATHA Litton Mark James 25,107 0.5619 25,107 0.5619 14,108
2024-09-05 ATHA Litton Mark James 5,032 0.5660 5,032 0.5660 2,848
2024-01-05 ATHA Litton Mark James 4,820 2.9100 4,820 2.9100 14,026
2024-01-05 ATHA Litton Mark James 4,820 2.9100 4,820 2.9100 14,026
2022-06-23 ATHA Litton Mark James 7,960 2.6900 7,960 2.6900 21,412

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ATHA / Athira Pharma, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Mark James Litton as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-07-02 2025-07-01 4 ATHA Athira Pharma, Inc.
Common Stock
S - Sale -25,123 325,802 -7.16 0.29 -7,374 95,623
2025-07-02 2025-06-30 4 ATHA Athira Pharma, Inc.
Common Stock
M - Exercise 108,334 350,925 44.66
2025-01-03 2025-01-02 4 ATHA Athira Pharma, Inc.
Common Stock
S - Sale -25,107 242,591 -9.38 0.56 -14,108 136,312
2025-01-03 2024-12-31 4 ATHA Athira Pharma, Inc.
Common Stock
M - Exercise 108,333 267,698 67.98
2024-09-05 2024-09-05 4 ATHA Athira Pharma, Inc.
Common Stock
S - Sale -5,032 159,365 -3.06 0.57 -2,848 90,201
2024-09-05 2024-09-03 4 ATHA Athira Pharma, Inc.
Common Stock
A - Award 20,000 164,397 13.85
2024-02-16 2024-01-05 4/A ATHA Athira Pharma, Inc.
Common Stock
S - Sale -4,820 144,397 -3.23 2.91 -14,026 420,195
2024-02-16 2024-01-04 4/A ATHA Athira Pharma, Inc.
Common Stock
A - Award 20,000 149,217 15.48
2024-01-08 2024-01-05 4 ATHA Athira Pharma, Inc.
Common Stock
S - Sale -4,820 144,397 -3.23 2.91 -14,026 420,195
2024-01-08 2024-01-04 4 ATHA Athira Pharma, Inc.
Common Stock
A - Award 20,000 149,217 15.48
2023-01-31 2022-11-18 4 ATHA Athira Pharma, Inc.
Common Stock
A - Award 662 129,217 0.51 2.74 1,814 354,055
2022-06-24 2022-06-23 4 ATHA Athira Pharma, Inc.
Common Stock
S - Sale -7,960 128,555 -5.83 2.69 -21,412 345,813
2022-06-24 2022-06-22 4 ATHA Athira Pharma, Inc.
Common Stock
A - Award 20,000 136,515 17.17
2022-06-24 2022-05-18 4 ATHA Athira Pharma, Inc.
Common Stock
A - Award 757 116,515 0.65 7.06 5,344 822,596
2022-01-31 2022-01-27 4 ATHA Athira Pharma, Inc.
Stock Option (Right to Buy)
A - Award 400,000 400,000
2022-01-31 2021-11-18 4 ATHA Athira Pharma, Inc.
Common Stock
A - Award 885 115,758 0.77 12.51 11,071 1,448,133
2021-08-19 2021-08-17 4 ATHA Athira Pharma, Inc.
Stock Option (Right to Buy)
M - Exercise -50,440 100,880 -33.33
2021-08-19 2021-08-17 4 ATHA Athira Pharma, Inc.
Common Stock
M - Exercise 50,440 114,873 78.28 1.35 68,094 155,079
2021-08-19 2021-05-18 4 ATHA Athira Pharma, Inc.
Common Stock
A - Award 867 64,433 1.36 14.45 12,528 931,057
2021-02-22 2021-02-18 4 ATHA Athira Pharma, Inc.
Stock Option (Right to Buy)
A - Award 85,000 85,000
2020-09-22 2020-09-22 4 ATHA Athira Pharma, Inc.
Series B-1 Preferred Stock
C - Conversion -6,563 0 -100.00
2020-09-22 2020-09-22 4 ATHA Athira Pharma, Inc.
Series B-1 Preferred Stock
C - Conversion -6,563 0 -100.00
2020-09-22 2020-09-22 4 ATHA Athira Pharma, Inc.
Series B-1 Preferred Stock
C - Conversion -6,563 0 -100.00
2020-09-22 2020-09-22 4 ATHA Athira Pharma, Inc.
Series B Preferred Stock
C - Conversion -13,126 0 -100.00
2020-09-22 2020-09-22 4 ATHA Athira Pharma, Inc.
Common Stock
C - Conversion 6,563 6,563
2020-09-22 2020-09-22 4 ATHA Athira Pharma, Inc.
Common Stock
C - Conversion 6,563 6,563
2020-09-22 2020-09-22 4 ATHA Athira Pharma, Inc.
Common Stock
C - Conversion 6,563 6,563
2020-09-22 2020-09-22 4 ATHA Athira Pharma, Inc.
Common Stock
C - Conversion 13,126 63,566 26.02
2020-09-17 3 ATHA Athira Pharma, Inc.
Common Stock
50,440
2019-02-08 2019-02-06 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Stock Option (right to buy)
A - Award 75,000 75,000
2019-02-08 2019-02-06 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Stock Option (right to buy)
A - Award 25,000 25,000
2018-08-08 2018-08-06 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Stock Option (right to buy)
A - Award 150,000 150,000
2018-06-05 2018-06-01 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -22,727 0 -100.00
2018-06-05 2018-06-01 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -4,474 102,189 -4.19 18.24 -81,587 1,863,498
2018-06-05 2018-06-01 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -18,253 106,663 -14.61 17.74 -323,825 1,892,298
2018-06-05 2018-06-01 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
M - Exercise X 22,727 124,916 22.24 0.99 22,500 123,667
2018-02-21 2018-02-16 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 75,000 75,000
2017-11-15 2017-11-13 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -16,519 0 -100.00
2017-11-15 2017-11-13 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -16,519 99,932 -14.19 10.80 -178,486 1,079,755
2017-11-15 2017-11-13 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
M - Exercise X 16,519 116,451 16.53 1.65 27,256 192,144
2017-10-18 2017-10-16 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -16,520 16,519 -50.00
2017-10-18 2017-10-16 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -16,520 99,932 -14.19 12.33 -203,703 1,232,232
2017-10-18 2017-10-16 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
M - Exercise X 16,520 116,452 16.53 1.65 27,258 192,146
2017-01-31 2017-01-27 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 60,000 60,000
2017-01-20 2017-01-18 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -1,498 33,039 -4.34
2017-01-20 2017-01-18 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -1,498 99,932 -1.48 23.10 -34,599 2,308,089
2017-01-20 2017-01-18 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
M - Exercise X 1,498 101,430 1.50 1.65 2,472 167,360
2017-01-09 2017-01-09 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -500 34,537 -1.43
2017-01-09 2017-01-09 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -500 99,932 -0.50 23.00 -11,500 2,298,436
2017-01-09 2017-01-09 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
M - Exercise X -500 100,432 -0.50 1.65 -825 165,713
2017-01-09 2017-01-06 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -1,326 35,037 -3.65
2017-01-09 2017-01-06 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -5,474 0 -100.00
2017-01-09 2017-01-06 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -6,800 99,932 -6.37 23.02 -156,520 2,300,195
2017-01-09 2017-01-06 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
M - Exercise X 1,326 106,732 1.26 1.65 2,188 176,108
2017-01-09 2017-01-06 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
M - Exercise X 5,474 105,406 5.48 1.26 6,925 133,339
2017-01-09 2017-01-05 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -2,216 5,474 -28.82
2017-01-09 2017-01-05 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -2,216 99,932 -2.17 23.00 -50,972 2,298,626
2017-01-09 2017-01-05 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
M - Exercise X 2,216 102,148 2.22 1.26 2,803 129,217
2016-10-19 2016-10-17 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -2,000 26,000 -7.14 27.50 -55,000 715,000
2016-10-19 2016-10-17 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -2,000 26,000 -7.14 27.50 -55,005 715,065
2016-10-19 2016-10-17 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -2,000 26,000 -7.14 27.50 -54,993 714,906
2016-07-14 2016-07-12 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise 25,000 0 -100.00
2016-07-14 2016-07-12 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
M - Exercise 25,000 99,567 33.53 0.38 9,625 38,333
2016-06-15 2016-06-13 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -200 28,000 -0.71 29.64 -5,928 829,920
2016-06-15 2016-06-13 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -1,800 28,200 -6.00 28.90 -52,012 814,862
2016-06-15 2016-06-13 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -100 28,000 -0.36 29.60 -2,960 828,800
2016-06-15 2016-06-13 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -100 28,000 -0.36 29.60 -2,960 828,800
2016-06-15 2016-06-13 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -1,900 28,100 -6.33 28.89 -54,900 811,944
2016-06-15 2016-06-13 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -1,900 28,100 -6.33 28.90 -54,903 811,986
2016-06-01 2016-05-31 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -19,720 25,000 -44.10
2016-06-01 2016-05-31 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -19,720 74,567 -20.91 30.05 -592,566 2,240,664
2016-06-01 2016-05-31 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
M - Exercise X 19,720 94,287 26.45 0.38 7,592 36,300
2016-06-01 2016-05-27 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -5,280 44,720 -10.56
2016-06-01 2016-05-27 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -5,280 74,567 -6.61 30.06 -158,693 2,241,148
2016-06-01 2016-05-27 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
M - Exercise X 5,280 79,847 7.08 0.38 2,033 30,741
2016-02-02 2016-01-29 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 50,000 50,000
2016-01-06 2016-01-04 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -25,000 50,000 -33.33
2016-01-06 2016-01-04 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -7,709 73,718 -9.47 31.86 -245,573 2,348,309
2016-01-06 2016-01-04 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -17,291 81,427 -17.52 31.19 -539,379 2,540,050
2016-01-06 2016-01-04 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
M - Exercise X 25,000 98,718 33.91 0.38 9,625 38,006
2015-10-05 2015-10-01 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -560 72,919 -0.76 32.81 -18,373 2,392,341
2015-10-05 2015-10-01 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -6,940 73,479 -8.63 32.22 -223,630 2,367,736
2015-09-28 2015-09-24 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -12,764 7,690 -62.40
2015-09-28 2015-09-24 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
M - Exercise 12,764 80,419 18.87 1.26 16,146 101,730
2015-07-06 2015-07-01 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -7,500 67,655 -9.98 51.10 -383,219 3,456,893
2015-06-08 2015-06-04 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -25,000 75,000 -25.00
2015-06-08 2015-06-04 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale -25,000 75,155 -24.96 44.27 -1,106,852 3,327,420
2015-06-08 2015-06-04 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
M - Exercise 25,000 100,155 33.26 0.38 9,625 38,560
2015-04-03 2015-04-01 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -7,500 74,359 -9.16 27.41 -205,552 2,037,957
2015-01-28 2015-01-27 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -2,300 81,859 -2.73 28.52 -65,602 2,334,840
2015-01-28 2015-01-26 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 35,000 35,000
2015-01-28 2015-01-26 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale X -5,200 84,159 -5.82 28.03 -145,732 2,358,590
2014-11-24 2014-11-20 4 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
S - Sale -30,000 88,484 -25.32 15.63 -469,011 1,383,332
2014-07-10 2014-07-08 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 25,000 25,000
2014-06-30 3/A ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
118,484
2014-06-30 3/A ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
30,000
2014-06-30 3/A ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
30,000
2014-06-30 3/A ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
30,000
2014-05-09 2014-05-07 4 ALDR ALDER BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 9,090 9,090
2014-05-07 3 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
416,968
2014-05-07 3 ALDR ALDER BIOPHARMACEUTICALS INC
Common Stock
416,968
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)